Cancer Letters

Cancer Letters

Volume 141, Issues 1–2, 1 July 1999, Pages 173-178
Cancer Letters

Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers

https://doi.org/10.1016/S0304-3835(99)00102-0Get rights and content

Abstract

The c-met proto-oncogene encoding the receptor for the hepatocyte growth factor is expressed in several cancers. In the present study, c-met protein (c-Met) was detected in eight of 22 (36%) cases of prostatic intraepithelial neoplasia (PIN), five of 15 (33%) latent and 17 of 21 (81%) clinical prostate cancers, including seven metastatic lesions, using an immunohistochemical method. All seven (100%) metastatic lesions investigated demonstrated strong staining, and a correlation between c-Met expression and histology was observed. These results suggest a significant relationship between c-Met expression and progression of prostate neoplasms, including latent cancers.

Introduction

While prostate cancer is one of the most common malignant diseases in American men, it is not frequent in Japan [1], [2], although its incidence has been increasing recently [3]. The similar incidence of latent prostate cancers between Japanese and Americans suggests that the difference in clinical disease is due to variation in the factors responsible for progression [4], [5].

The hepatocyte growth factor (HGF) is an acidic protein growth factor whose functions encompass stimulation of cell motility and scattering, mitogenesis, morphogenesis and invasion, as well as paradoxical inhibition of tumor growth [6], [7], [8], [9], [10], [11]. However, HGF has been reported to provoke prostate epithelial cell proliferation [12]. The c-Met receptor for HGF is a tyrosine kinase comprising disulfide-linked 50-kDa α-chain and 145-kDa β-chain subunits [13]. It has been reported to be overexpressed in carcinomas of the gastrointestinal tract, thyroid cancers and in malignant melanomas. Recent studies have also revealed c-met gene amplification in various human cancers [14], [15], [16], [17] and interestingly, this was associated with advanced tumor stage [14].

To our knowledge, there have only been a few studies of c-Met expression in prostate cancers [18], [19], [20], [21]; prostatic intraepithelial neoplasia (PIN) and clinical prostate cancers were investigated but not latent carcinomas. In the present study, we focused on latent cancer and PIN, and examined 22 PIN, 15 latent, 14 clinical cancers and seven metastatic lesions using an immunohistochemical method with c-Met antibodies to clarify their levels of c-Met expression.

Section snippets

Tissue samples

A total of 36 tumor samples were available for this study, including 15 latent and 14 clinical prostate cancers, and seven metastatic lesions. The specimens were obtained by surgical resection or autopsy at Mie University Hospital between 1992 and 1995. Metastatic lesions were resected from the lungs and/or bone marrow at autopsy. Unfortunately, their primary lesions were not available because of previous resections. Of the 14 clinical prostate cancers two were stage B1, one stage B2, six stage

Pathological findings of prostate cancers

Classification of the lesions examined was made according to ‘The General Rules for Clinical and Pathological Studies on Prostatic Cancer’, the Gleason system, and the WHO histological subtyping criteria. Twelve PIN (80%) were detected in latent cancer samples and 10 (71%) in clinical samples. Of these, 16 were diagnosed as low-grade PIN and six as high grade. Of the 15 latent prostate cancers, 13 were graded as well differentiated, and two as poorly differentiated. The 15 cancers comprised 12

Discussion

Previous reports have indicated an involvement of HGF and c-Met in progression of tumor cells to a more malignant phenotype [10], [14], [15]. The present results are also of interest in this context: immunoreactivity significantly increased with the Gleason score and was particular strong in metastases.

The significant association of c-Met expression with prostate tumor progression observed in this study is in line with findings for malignant melanomas and thyroid cancers [15], [16]. In the rat

Acknowledgements

The expert technical advice of Dr. J. Morita, Department of Pathology, Mie University School of Medicine, is greatly appreciated.

References (27)

  • K.M. Weidner et al.

    Evidence for the identity of human scatter factor and human hepatocyte growth factor

    Proc. Natl. Acad. Sci. USA

    (1991)
  • M. Stoker et al.

    Scatter factor is a fibroblast-derived modulator of epithelial cell mobility

    Nature

    (1987)
  • S. Bellusci et al.

    Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity

    Oncogene

    (1994)
  • Cited by (50)

    • Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin–mediated prostatic tumorigenesis

      2020, Journal of Biological Chemistry
      Citation Excerpt :

      An increase in expression of both the Met receptor and the HGF ligand has been observed at sites of prostate cancer bone metastasis, suggesting that this pathway may be active during bone metastasis (8). Up-regulation of Met expression has been observed in most metastatic prostate cancer lesions (6, 8–11). A significant challenge within the field of prostate cancer has been the lack of clinically relevant models for examining the biological role of Met in prostate tumor progression and metastasis.

    • Neoplasms of the Prostate

      2020, Urologic Surgical Pathology
    • Prostate

      2009, Modern Surgical Pathology
    • Chapter 1 The Function, Proteolytic Processing, and Histopathology of Met in Cancer

      2009, Advances in Cancer Research
      Citation Excerpt :

      Some reports indicate a correlation between Met expression and higher grade (Pisters et al., 1995; Watanabe et al., 1999). Interestingly, all of these studies found Met to be highly expressed in most metastatic lesions (Humphrey et al., 1995; Knudsen et al., 2002; Pisters et al., 1995; Watanabe et al., 1999), and Knudsen et al., 2002 observed higher Met expression in bone metastases than lymph node metastases. Additionally, Watanabe et al. (1999) reported more intense staining of Met along the invasive fronts similar to what has been described in melanoma, breast, lung, and colon cancer.

    • Prostate

      2009, Modern Surgical Pathology
    View all citing articles on Scopus
    View full text